Professional Media briefs: April 2012

Professional Media briefs: April 2012
Professional Media briefs: April 2012
Elsevier is launching the cross-disciplinary journal Fellowship of Postgraduate Medicine, Health Policy and Technology. Editor-in-Chief Wendy Currie's background includes academia, business consulting and the non-profit sector. The inaugural issue focuses on Electronic Health Records and will feature an interview with Sir Michael Rawlins, the chairman of NICE.

Monthly Prescribing Reference has released a Drugs & Bugs app that connects healthcare providers to the profiles of more than 100 antibiotics and almost 200 pathogens. The Apple- and Android- friendly app can also be used on the Kindle Fire and NOOK. It provides comparative charts by drug class and can be searched by pathogen, infection and drug names. Both MPR and MM&M are owned by Haymarket Media.

Journal EMBO Molecular Medicine is converting to an open-access model as part of Wiley-Blackwell's Wiley Open Access publishing program, Wiley and EBMO said. This is the second of EMBO's four journals to convert from a subscription-based model to open-access. Future articles will be published under the Creative Commons ­Attribution Non-Commercial License.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.